Clinical trial NCT06592378: Opioid Management for Discharged Emergency Department Patients
Official title: Integration of an Opioid Dispensing, Monitoring, and Disposal Platform with a Hospital Pharmacy to Reduce Opioid Use by Discharged Emergency Department Patients
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Bone Fractures
Keywords: opioids
fractures
pain
Lead sponsor: Addinex Technologies, Inc.
Sponsor class: INDUSTRY
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2024-09-19
Enrollment: 100
Sex: ALL
Minimum age (years): 6
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this study is to analyze the use of the Addinex system for opioid dispensing after ambulatory care to determine whether it will reduce opioid consumption, increase pill disposal, show variables that may predict opioid consumption, and determine whether this intervention is acceptable to patients.

Detailed description: Prescription opioids remain a popular drug class with 143 million (M) opioid prescriptions written in 2020. In that same year, 8.7 million people (2.6% of the US population) misused prescription pain relievers, and overdose deaths from opioids continue to rise to 83,695 in 2022. Across six studies, 67% to 92% of patients prescribed opioids reported unused pills. In 2017, patients were prescribed 3.3 billion excess pills, yet no more than 9% of patients properly disposed of their unused opioids. Despite attempts to reduce overprescribing, increase disposal, and decrease diversion, these issues still contribute to increasing misuse, addiction, and overdose deaths.

Addinex Technologies has developed a novel system to reduce the use of opioids through controlling, monitoring, and disposing of excess opioids. The unique "closed-loop" system starts with clinicians prescribing opioids with the Addinex system. Addinex's partner pharmacy then fills the patented dispenser and delivers it to the patient. The patient uses the Addinex app to access each individual dose code and to obtain education and feedback. Finally, the patient returns the dispenser with any excess pills in a DEA-approved mailer to Addinex's partner disposal company. In a study with Columbia University Medical Center using the Addinex system with 30 post-surgical cancer patients, results showed 70% fewer pills used than prescribed, 60% fewer refills for the same surgeries, and an 84% excess pill disposal rate.

Addinex is now partnering with Brown Emergency Medicine and Rhode Island Hospital ("Brown") to perform a feasibility study using Addinex\&#39;s system. We will conduct a clinical trial involving 100 patients with extremity fractures treated by the emergency department. Half the patients (25 adults and 25 minors) will utilize the Addinex system, while the other half will have their opioids dispensed in a standard pill bottle as the control group. Addinex's system promotes the return of medication using a pre-paid disposal mailer once patients have completed their course of treatment. The clinical study\&#39;s main goals involve evaluating the system\&#39;s effectiveness with patients obtaining same day treatment. This evaluation will encompass an analysis of medication consumption, disposal rates, pain levels, the impact of monitoring policies, and ensuring that the established commercial protocols function seamlessly. Ultimately, the project aims to demonstrate that the Addinex system can successfully operate within the broader hospital environment (same day and scheduled procedures), controlling and monitoring opioid usage, promoting patient well-being, and lowering costs.

Eligibility criteria: Inclusion Criteria:

* Ages six years and older
* Ability to swallow pills
* Isolated bone fracture
* Planned to receive opioids in the post-treatment period
* Not taking opioids daily prior to the procedure
* English or Spanish-speaking
* Able to give informed consent or a parent that can give informed consent
* Ownership of and comfort using apps on a smartphone with compatible operating system
* WIFI or cellular access
* Patient not admitted to hospital

Exclusion Criteria:

* Recent opioid use (last 30 days or 2 or more prescriptions in the past 3 months
* Impaired decisional capacity
* In police custody
* Ward of the state

Primary outcomes:
measure: Median pill consumption
timeFrame: One month post treatment
Secondary outcomes:
measure: Median disposal of opioids
timeFrame: 12 months post treatment
Other outcomes:
Locations:
city: Providence
country: United States
facility: Rhode Island Hospital/Lifespan
state: Rhode Island
Study officials:
References: